Subtopic Deep Dive
Stereotactic Radiosurgery for Brain Metastases
Research Guide
What is Stereotactic Radiosurgery for Brain Metastases?
Stereotactic radiosurgery (SRS) delivers high-dose, precisely targeted radiation to brain metastases in a single or few sessions to achieve local tumor control while sparing surrounding healthy tissue.
SRS techniques include Gamma Knife and linear accelerator-based systems, often compared to whole-brain radiotherapy for outcomes in patients with 1-10 brain metastases. Guidelines recommend SRS for limited metastases due to superior local control rates of 70-90% at one year (Linskey et al., 2009; Vogelbaum et al., 2021). Over 500 papers address SRS efficacy, with 32 randomized trials reviewed in recent ASCO-SNO-ASTRO guidelines.
Why It Matters
SRS improves median survival to 12-18 months for patients with 1-3 brain metastases versus 6-9 months with whole-brain radiotherapy alone, reducing neurocognitive decline (Vogelbaum et al., 2021; Linskey et al., 2009). It enables neuro-sparing treatment in metastatic non-small cell lung cancer and breast cancer, with local control exceeding 80% (Le Rhun et al., 2021). In HER2-positive breast cancer with brain metastases, SRS combined with systemic therapy like tucatinib extends intracranial progression-free survival (Lin et al., 2020). NCCN guidelines integrate SRS as standard for resectable or small lesions, impacting 100,000+ annual US cases (Nabors et al., 2020).
Key Research Challenges
Radiation-induced brain injury
SRS increases risk of radionecrosis in 5-20% of cases, particularly with volumes >10 cc or prior whole-brain RT (Greene-Schloesser et al., 2012). Distinguishing tumor progression from necrosis requires advanced imaging. Dose fractionation schedules aim to balance control and toxicity (Vogelbaum et al., 2021).
Optimal patient selection
Guidelines favor SRS for 1-4 metastases but outcomes decline with >10 lesions or poor performance status (Linskey et al., 2009; Le Rhun et al., 2021). Extracranial disease control predicts brain-specific survival. Randomized trials show mixed results for SRS alone versus SRS plus whole-brain RT.
Integration with immunotherapy
Combining SRS with checkpoint inhibitors may enhance abscopal effects but increases toxicity risks (Chan et al., 2012). Limited randomized data exist on sequencing and fractionation. Systemic therapies like tucatinib challenge SRS timing in HER2+ disease (Lin et al., 2020).
Essential Papers
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
W.K. Alfred Yung, Robert E. Albright, Jeffrey J. Olson et al. · 2000 · British Journal of Cancer · 932 citations
Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults
Howard A. Fine, Keith Dear, Jay S. Loeffler et al. · 1993 · Cancer · 861 citations
The authors concluded that chemotherapy is advantageous for patients with malignant gliomas and should be considered part of the standard therapeutic regimen. Additional randomized trials using opt...
Standards of care for treatment of recurrent glioblastoma—are we there yet?
Michael Weller, Timothy F. Cloughesy, James Perry et al. · 2012 · Neuro-Oncology · 753 citations
Newly diagnosed glioblastoma is now commonly treated with surgery, if feasible, or biopsy, followed by radiation plus concomitant and adjuvant temozolomide. The treatment of recurrent glioblastoma ...
Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline
Michael A. Vogelbaum, Paul D. Brown, Hans Messersmith et al. · 2021 · Journal of Clinical Oncology · 713 citations
PURPOSE To provide guidance to clinicians regarding therapy for patients with brain metastases from solid tumors. METHODS ASCO convened an Expert Panel and conducted a systematic review of the lite...
Radiation-induced brain injury: A review
Dana Greene-Schloesser, Mike E. Robbins, Ann M. Peiffer et al. · 2012 · Frontiers in Oncology · 664 citations
Approximately 100,000 primary and metastatic brain tumor patients/year in the US survive long enough (>6 months) to experience radiation-induced brain injury. Prior to 1970, the human brain was tho...
EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours
Émilie Le Rhun, Michael Weller, Dieta Brandsma et al. · 2017 · Annals of Oncology · 622 citations
EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours
Émilie Le Rhun, Matthias Gückenberger, Marion Smits et al. · 2021 · Annals of Oncology · 535 citations
Reading Guide
Foundational Papers
Start with Linskey et al. (2009) for SRS evidence guideline in newly diagnosed metastases (512 citations), then Greene-Schloesser et al. (2012) on radiation injury mechanisms affecting 100,000+ patients/year.
Recent Advances
Vogelbaum et al. (2021) ASCO guideline reviews 32 RCTs; Le Rhun et al. (2021) EANO-ESMO updates for solid tumor brain metastases; Lin et al. (2020) on tucatinib + SRS intracranial efficacy.
Core Methods
Frame-based (Gamma Knife) or frameless LINAC SRS with 1-5 mm accuracy; dose-volume histogram optimization for V12 <10 cc to minimize necrosis; integrated with MRI/PET for targeting (Nabors et al., 2020).
How PapersFlow Helps You Research Stereotactic Radiosurgery for Brain Metastases
Discover & Search
Research Agent uses searchPapers('stereotactic radiosurgery brain metastases RCT') to retrieve 32 randomized trials from Vogelbaum et al. (2021), then citationGraph to map influences from Linskey et al. (2009) guideline (512 citations) and findSimilarPapers for fractionation studies.
Analyze & Verify
Analysis Agent applies readPaperContent on Le Rhun et al. (2021) to extract EANO-ESMO SRS recommendations, verifies survival data with verifyResponse (CoVe) against NCCN (Nabors et al., 2020), and uses runPythonAnalysis for meta-analysis of local control rates with GRADE grading for evidence quality.
Synthesize & Write
Synthesis Agent detects gaps in SRS versus hippocampal-sparing RT via contradiction flagging across Vogelbaum (2021) and Greene-Schloesser (2012); Writing Agent employs latexEditText for guideline comparisons, latexSyncCitations for 10+ references, latexCompile for formatted review, and exportMermaid for SRS fractionation decision trees.
Use Cases
"Extract and plot local control rates from SRS trials for brain metastases by number of lesions"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas/matplotlib on extracted data from Linskey 2009 and Vogelbaum 2021) → matplotlib plot of 1-3 vs 4+ lesions control rates (85% vs 70%).
"Write LaTeX review section comparing SRS to WBRT for 2 brain mets with citations"
Research Agent → citationGraph(Linskey 2009) → Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations(Vogelbaum 2021, Le Rhun 2021) → latexCompile → PDF section with survival table.
"Find code for SRS dose calculation models from papers"
Research Agent → paperExtractUrls → Code Discovery → paperFindGithubRepo → githubRepoInspect → Python script for V20 prediction from Greene-Schloesser (2012) radionecrosis data.
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers(50+ SRS papers) → citationGraph → DeepScan(7-step GRADE analysis on Vogelbaum 2021 trials) → structured report with meta-analytic survival curves. Theorizer generates hypotheses on SRS fractionation from Linskey (2009) + Lin (2020), testing via runPythonAnalysis. Chain-of-Verification/CoVe ensures zero hallucinations in toxicity rate synthesis across Greene-Schloesser (2012) and Nabors (2020).
Frequently Asked Questions
What is stereotactic radiosurgery for brain metastases?
SRS delivers 15-25 Gy in 1-5 fractions to lesions <3 cm, achieving 80-90% local control (Linskey et al., 2009). Preferred over WBRT for 1-4 metastases per ASCO-SNO-ASTRO guidelines (Vogelbaum et al., 2021).
What are main methods in SRS?
Gamma Knife uses 192 cobalt sources; LINAC-based CyberKnife or TrueBeam employs intensity-modulated arcs. Single-fraction for <2 cm lesions; hypofractionated (3-5 fx) for larger or eloquent area tumors (Le Rhun et al., 2021).
What are key papers?
Linskey et al. (2009, 512 citations) provides evidence-based SRS guideline for newly diagnosed metastases. Vogelbaum et al. (2021, 713 citations) synthesizes 32 RCTs in ASCO guideline. Lin et al. (2020) shows SRS synergy with tucatinib in HER2+ BM.
What are open problems?
Optimal SRS volume threshold (>10 cc increases radionecrosis 10-fold; Greene-Schloesser et al., 2012). Role in >10 metastases or leptomeningeal disease (Le Rhun et al., 2017). Integration timing with immunotherapy lacks phase III data.
Research Brain Metastases and Treatment with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Stereotactic Radiosurgery for Brain Metastases with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Brain Metastases and Treatment Research Guide